BioSpace News Archive

Genetown

Verastem Announces Clinical Data From the Pivotal Phase III DUO Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Verastem today announced the presentation of the results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) at the American Society of Hematology (ASH) 2017 Annual Meeting held December 9-12, 2017 in Atlanta.

December 10, 2017
·
13 min read
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

bluebird bio announced that updated clinical results from HGB-206, the company’s ongoing Phase 1 multicenter study of its LentiGlobin gene therapy product candidate in patients with severe sickle cell disease (SCD), will be discussed in an oral presentation during the 59th Annual Meeting of the American Society of Hematology (ASH).

December 10, 2017
·
10 min read
Pharm Country

AstraZeneca’s CALQUENCE (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials

The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta.

December 10, 2017
·
12 min read